CA1252045A - Suspension fluidisee de magaldrate - Google Patents

Suspension fluidisee de magaldrate

Info

Publication number: CA1252045A
Authority: CA; Canada
Prior art keywords: magaldrate; fluidizer; composition; gel; antacid
Prior art date: 1984-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000493152A

Other languages

English (en)

Inventor

Chien-Chin Wu

Gerald L. Reuter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth LLC

Original Assignee

American Home Products Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-17

Filing date

1985-10-17

Publication date

1989-04-04

1985-10-17 Application filed by American Home Products Corp filed Critical American Home Products Corp

1989-04-04 Application granted granted Critical

1989-04-04 Publication of CA1252045A publication Critical patent/CA1252045A/fr

Status Expired legal-status Critical Current

Links

229960004018 magaldrate Drugs 0.000 title claims abstract description 91
JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 title claims abstract description 90
239000000725 suspension Substances 0.000 title claims abstract description 70
229940069428 antacid Drugs 0.000 claims abstract description 89
239000003159 antacid agent Substances 0.000 claims abstract description 89
239000000203 mixture Substances 0.000 claims abstract description 75
230000001458 anti-acid effect Effects 0.000 claims abstract description 74
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 70
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 33
238000000034 method Methods 0.000 claims abstract description 24
239000012530 fluid Substances 0.000 claims abstract description 17
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 15
229940024546 aluminum hydroxide gel Drugs 0.000 claims abstract description 14
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims abstract description 14
238000002156 mixing Methods 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
239000001508 potassium citrate Substances 0.000 claims description 9
229960002635 potassium citrate Drugs 0.000 claims description 9
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 9
235000011082 potassium citrates Nutrition 0.000 claims description 9
239000001509 sodium citrate Substances 0.000 claims description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 4
230000008569 process Effects 0.000 abstract description 3
239000000499 gel Substances 0.000 description 45
239000000243 solution Substances 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 9
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
239000000600 sorbitol Substances 0.000 description 8
235000012254 magnesium hydroxide Nutrition 0.000 description 7
238000006386 neutralization reaction Methods 0.000 description 7
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
229910052782 aluminium Inorganic materials 0.000 description 6
229940024545 aluminum hydroxide Drugs 0.000 description 6
235000015165 citric acid Nutrition 0.000 description 6
239000007788 liquid Substances 0.000 description 6
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 6
239000000347 magnesium hydroxide Substances 0.000 description 6
229910001862 magnesium hydroxide Inorganic materials 0.000 description 6
239000000047 product Substances 0.000 description 6
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 6
229940081974 saccharin Drugs 0.000 description 6
235000019204 saccharin Nutrition 0.000 description 6
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
229940024548 aluminum oxide Drugs 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
-1 magnesium hydroxide antacid Chemical class 0.000 description 5
239000000375 suspending agent Substances 0.000 description 5
241000220479 Acacia Species 0.000 description 4
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 4
235000010643 Leucaena leucocephala Nutrition 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000005243 fluidization Methods 0.000 description 4
210000004211 gastric acid Anatomy 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
239000011707 mineral Substances 0.000 description 4
235000010755 mineral Nutrition 0.000 description 4
239000007967 peppermint flavor Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
239000000230 xanthan gum Substances 0.000 description 4
235000010493 xanthan gum Nutrition 0.000 description 4
229920001285 xanthan gum Polymers 0.000 description 4
229940082509 xanthan gum Drugs 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical class O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 3
208000000718 duodenal ulcer Diseases 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
238000001879 gelation Methods 0.000 description 3
239000006194 liquid suspension Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229940083037 simethicone Drugs 0.000 description 3
238000003756 stirring Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
229910052599 brucite Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000011049 filling Methods 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
229960001545 hydrotalcite Drugs 0.000 description 2
229910001701 hydrotalcite Inorganic materials 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006069 physical mixture Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000034991 Hiatal Hernia Diseases 0.000 description 1
206010020028 Hiatus hernia Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020601 Hyperchlorhydria Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000011229 interlayer Substances 0.000 description 1
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000003801 milling Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229910001725 motukoreaite Inorganic materials 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
NNGFFDRXGAELQA-UHFFFAOYSA-A pentaaluminum;decamagnesium;hentriacontahydroxide;disulfate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O NNGFFDRXGAELQA-UHFFFAOYSA-A 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
229910001950 potassium oxide Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000011012 sanitization Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000493152A 1984-10-17 1985-10-17 Suspension fluidisee de magaldrate Expired CA1252045A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66164884A	1984-10-17	1984-10-17
US661,648		1984-10-17

Publications (1)

Publication Number	Publication Date
CA1252045A true CA1252045A (fr)	1989-04-04

Family

ID=24654494

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000493152A Expired CA1252045A (fr)	1984-10-17	1985-10-17	Suspension fluidisee de magaldrate

Country Status (1)

Country	Link
CA (1)	CA1252045A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111874938A (zh) *	2020-08-04	2020-11-03	安徽乐橙信息科技有限公司	一种镁铜羟基硫酸盐纳米花状材料的制备方法

1985
- 1985-10-17 CA CA000493152A patent/CA1252045A/fr not_active Expired

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111874938A (zh) *	2020-08-04	2020-11-03	安徽乐橙信息科技有限公司	一种镁铜羟基硫酸盐纳米花状材料的制备方法

Legal Events

Date	Code	Title	Description
2006-04-04	MKEX	Expiry

Publication	Publication Date	Title
CA1259919A (fr)	1989-09-26	Compose antiacide rehydratable
US4885281A (en)	1989-12-05	Sucralfate suspension
US4704278A (en)	1987-11-03	Fluidized magaldrate suspension
US4869902A (en)	1989-09-26	Antacid composition
US3579634A (en)	1971-05-18	Novel antacid compositions and methods for their administration
AU607132B2 (en)	1991-02-28	Process for the preparation of a viscosity-stable antacid composition
EP0179858B1 (fr)	1992-07-01	Composition antacide
IL32020A (en)	1972-11-28	Antacid compositions
US4465667A (en)	1984-08-14	Process for the preparation of gastric acid neutralizing agents, gastric acid neutralizing agents, and a method for treating hyperacidity and disorders related thereto
GB1582737A (en)	1981-01-14	Concentrated magnesium hydroxide suspensions or emulsions and method for production thereof
EP0178895B1 (fr)	1991-03-06	Compositions de magaldrate fluidisées et réhydratables
US4857324A (en)	1989-08-15	Exogenously acidified antacid compositions having cytoprotective properties
EP0715520B1 (fr)	2000-06-28	Utilisatioin d'une suspension a base de gel de sucralphate comme antiacide
EP0220849B1 (fr)	1991-02-27	Compositions pharmaceutiques à propriétés cytopréservatrices
US6110505A (en)	2000-08-29	Translucent antacid suspension containing co-dried dihydroxy aluminum sodium carbonate
JPS6287515A (ja)	1987-04-22	細胞保護特性を有する外因的酸性化制酸剤組成物
JPS61263920A (ja)	1986-11-21	医薬組成物
CA2214343C (fr)	2007-05-01	Compositions pharmaceutiques liquides aqueuses contenant de l'alginate de sodium et du bicarbonate de potassium

CA1252045A - Suspension fluidisee de magaldrate - Google Patents

Info

Links

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=24654494

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Similar Documents

Legal Events